uBriGene社はATMP分野において豊富な経験を有し、バイオテクノロジー開発・製造の専門知識で世界的に認められています。ATMP製造、品質管理試験、規制申請、そして早期発見から商業化までのサポートにおいて豊富な経験を持つuBriGene社は、お客様の治療プログラムを研究段階から臨床段階へと加速させるお手伝いをいたします。uBriGene社は、プラスミド製品、AAV 製品、レンチウイルス製品、iPSC 製品、遺伝子編集製品、全ヌクレアーゼなども提供しています。
1. プラスミド製品
| 品名 | 品番 | 説明 | グレード | |
| AAVプラスミド製品 | ||||
| YM-HELPER2.0 | 1302YM-HELPER2.0 | AAV Helper plasmid, providing adeno helper function for AAV packaging | ☑Research | ☑GMP |
| YM-RC1 | 1302YM-RC1 | AAV Rep-Cap1 plasmid, providing Rep/Cap for AAV1 serotype packaging | ☑Research | ☑GMP |
| YM-RC2 | 1302YM-RC2 | AAV Rep-Cap2 plasmid, providing Rep/Cap for AAV2 serotype packaging | ☑Research | ☑GMP |
| YM-RC3 | 1302YM-RC3 | AAV Rep-Cap3 plasmid, providing Rep/Cap for AAV3 serotype packaging | ☑Research | ☑GMP |
| YM-RC4 | 1302YM-RC4 | AAV Rep-Cap4 plasmid, providing Rep/Cap for AAV4 serotype packaging | ☑Research | ☑GMP |
| YM-RC5 | 1302YM-RC5 | AAV Rep-Cap5 plasmid, providing Rep/Cap for AAV5 serotype packaging | ☑Research | ☑GMP |
| YM-RC6 | 1302YM-RC6 | AAV Rep-Cap6 plasmid, providing Rep/Cap for AAV6 serotype packaging | ☑Research | ☑GMP |
| YM-RC7 | 1302YM-RC7 | AAV Rep-Cap7 plasmid, providing Rep/Cap for AAV7 serotype packaging | ☑Research | ☑GMP |
| YM-RC8 | 1302YM-RC8 | AAV Rep-Cap8 plasmid, providing Rep/Cap for AAV8 serotype packaging | ☑Research | ☑GMP |
| YM-RC9 | 1302YM-RC9 | AAV Rep-Cap9 plasmid, provide Rep-Cap for AAV9 packaging | ☑Research | ☑GMP |
| YM-RC10 | 1302YM-RC10 | AAV Rep-Cap10 plasmid, provide Rep-Cap for AAV10 packaging | ☑Research | ☑GMP |
| YM-RC11 | 1302YM-RC11 | AAV Rep-Cap11 plasmid, provide Rep-Cap for AAV11 packaging | ☑Research | ☑GMP |
| YM-RC12 | 1302YM-RC12 | AAV Rep-Cap12 plasmid, provide Rep-Cap for AAV12 packaging | ☑Research | ☑GMP |
| YM-RC13 | 1302YM-RC13 | AAV Rep-Cap13 plasmid, provide Rep-Cap for AAV13 packaging | ☑Research | ☑GMP |
| YM-RC myoAAV 1A | 1302YM-RCmyoAAV1A | AAV Rep-Cap myoAAV 1A plasmid, providing Rep/Cap for myoAAV 1A serotype packaging | ☑Research | ☐GMP |
| YM-7m8 | 1302YM-7m8 | AAV Rep-Cap 7m8 plasmid, providing Rep/Cap for AAV 7m8 serotype packaging | ☑Research | ☐GMP |
| AAV2/Anc80L65AAP | 1302AAV2/Anc80L65AAP | AAV Rep-Cap Anc80L65AAP plasmid, providing Rep/Cap for AAV Anc80L65 serotype packaging | ☑Research | ☐GMP |
| RC-ANC80 | 1302YM-ANC80 | AAV Rep-Cap Anc80 plasmid, providing Rep/Cap for AAV Anc80 serotype packaging | ☑Research | ☐GMP |
| pscAV-CMV-eGFP | 1302pscAV-CMV-GFP | scAAV transfer plasmid containing CMV driven eGFP | ☑Research | ☐GMP |
| YM-AAV-GFP | 1302YM-AAV-GFP | AAV transfer plasmid containing CAG driven eGFP | ☑Research | ☐GMP |
| レンチウイルスパッケージングプラスミド製品 | ||||
| Hex-VSVG | 1302HEX-VSVG | pVSV-G envelope plasmid for pseudo lentivirus packaging | ☑Research | ☑GMP |
| Hex-MDL | 1302HEX-MDL | pGag-Pol plasmid for lentivirus packaging | ☑Research | ☑GMP |
| Hex-Rev | 1302HEX-REV | pRev plasmid for lentivirus packaging | ☑Research | ☑GMP |
2. AAV製品
| 品名 | 品番 | 説明 | 力価 | サイズ |
| AAV1-luciferase | 1305AAV1-luciferase | AAV1 virus expressing CMV driven luciferase | >1E13 vg/mL | 500µL |
| MyoAAV 1A-GFP | 1305MyoAAV 1A-GFP | MyoAAV 1A expressing CAG driven GFP | >1E13 vg/mL | 500µL |
| AAV2-CAG-GFP | 1305AAV2-GFP | AAV2 virus expressing CAG driven GFP | >5E12 vg/mL | 500µL |
| AAV8-CAG-GFP | 1305AAV8-GFP | AAV8 virus expressing CAG driven GFP | >1E13 vg/mL | 500µL |
| AAV9-CAG-GFP | 1305AAV9-GFP | AAV9 virus expressing CAG driven GFP | >1E13 vg/mL | 500µL |
3. レンチウイルス製品
| 品名 | 品番 | 説明 | サイズ | |
| GFP Lentivirus | LV-CMV-C-GFP-E7 | 1305LV-CMV-C-GFP-E7 | Lentivirus, expressing CMV-GFP, Neomycin resistance, 10^7 TU/mL | 200µL |
| LV-CMV-C-GFP-E8 | 1305LV-CMV-C-GFP-E8 | Lentivirus, expressing CMV-GFP, Neomycin resistance, 10^8 TU/mL | 200µL | |
| LV-CMV-C-GFP-E9 | 1305LV-CMV-C-GFP-E9 | Lentivirus, expressing CMV-GFP, Neomycin resistance, 10^9 TU/mL | 100µL | |
| Luciferase -mWasabi Lentivirus | LV-CMV-Luciferase-mWasabi-E7 | 1305LV-CMV-Luciferase-mWasabi-E7 | Lentivirus, expressing CMV-Luciferase-mWasabi, blasticidin resistance, 10^7 TU/mL | 200µL |
| LV-CMV-Luciferase-mWasabi-E8 | 1305LV-CMV-Luciferase-mWasabi-E8 | Lentivirus, expressing CMV-Luciferase-mWasabi, blasticidin resistance, 10^8 TU/mL | 200µL | |
| LV-CMV-Luciferase-mWasabi-E9 | 1305LV-CMV-Luciferase-mWasabi-E9 | Lentivirus, expressing CMV-Luciferase-mWasabi, blasticidin resistance, 10^9 TU/mL | 100µL | |
| Luciferase Lentivirus | LV-CMV-Luciferase-E7 | 1305LV-CMV-Luciferase-E7 | Lentivirus, expressing CMV-Luciferase, 10^7 TU/mL | 200µL |
| LV-CMV-Luciferase-E8 | 1305LV-CMV-Luciferase-E8 | Lentivirus, expressing CMV-Luciferase, 10^8 TU/mL | 200µL | |
| LV-CMV-Luciferase-E9 | 1305LV-CMV-Luciferase-E9 | Lentivirus, expressing CMV-Luciferase, 10^9 TU/mL | 100µL | |
| Raji-Luc cells | Raji-LUC | Raji-LUC | Raja cells stably expressed with luciferase and mWasabi, blasticidin resistance, single cell colonies isolated using flow cytometry. | 12E6 cells/mL 1mL |
4. iPSC製品
| 品名 | 品番 | 説明 | サイズ | グレード | ||
| iPSC-RPM- mRNA Kits | For Fibroblasts | iPSC-RPM-RNA-S | Efficient iPSC reprogramming cocktail mRNA | Trial size 2x60uL (1 x iPSC reprogramming) | ☑Research | ☐GMP |
| iPSC-RPM-RNA | Standard size 8x60uL (5 x iPSC reprogramming) | ☑Research | ☑GMP | |||
| iPSC- reprogram- RNA-LNP | For Fibroblasts | iPSC-RPM-mRNA-LNP-FB-S | Efficient iPSC reprogramming mRNA-LNP cocktail for fibroblasts, can be directly added to cells | Trial size 2x60uL (1 x iPSC reprogramming) | ☑Research | ☐GMP |
| iPSC-RPM-mRNA-LNP-FB | Standard size 8x60uL (5 x iPSC reprogramming) | ☑Research | ☑GMP | |||
| For PBMCs and other difficult-to-reprogram cells | iPSC-RPM-RNA-LNP-V2-S | Efficient iPSC reprogramming RNA-LNP kit for PBMCs, difficult-to-reprogram, and disease-derived cells, can be directly added to cells | Trial size 1x80uL RNA-LNP cocktail, 1x30uL enhancer B (2 x iPSC reprogramming) | ☑Research | ☐GMP | |
| iPSC-RPM-RNA-LNP-V2 | Standard size 3x80uL RNA-LNP cocktail, 1 x enhancer B (80 uL) (6 x iPSC reprogramming reactions) | ☑Research | ☑GMP | |||
| PBMC-LNP-Enhancer | Enhancer B | 80uL / vial | ☑Research | ☑GMP | ||
| PBMC-Comp-Media-01 | Serum-free, Xeno-free, complete PBMC culture medium supplemented with hematopoietic growth factors, ready to use | 50mL / vial | ☑Research | ☐GMP | ||
5. 遺伝子編集製品(Casタンパク質、mRNA)
| 品名 | 品番 | 説明 | グレード | |
| Ubri-Cas9 | 1308Ubri-Cas9 | spCas9 Protein, high quality and tested for efficient gene editing | ☑Research | ☑GMP |
| Ubri-Cas12a | 1308Ubri-Cas12a | Cas12a Protein, high quality and tested for efficient gene editing | ☑Research | ☑GMP |
| Ubri-Cas13a | 1308Ubri-Cas13a | Cas13a Protein, high quality and tested for efficient gene editing | ☑Research | ☑GMP |
| Ubri-Cas14 | 1308Ubri-Cas14 | Cas14 Protein, high quality and tested for efficient gene editing | ☑Research | ☑GMP |
| spCas9-mRNA | spCas9-mRNA | Cas9 mRNA, ultra-pure, tested for high gene editing efficiency | ☑Research | ☑GMP |
| Cas12a-mRNA | Cas12a-mRNA | Cas12a mRNA, ultra-pure, tested for high gene editing efficiency | ☑Research | ☑GMP |
| Cas13a-mRNA | Cas13a-mRNA | Cas13a mRNA, ultra-pure, tested for high gene editing efficiency | ☑Research | ☑GMP |
| Cas14-mRNA | Cas14-mRNA | Cas14 mRNA, ultra-pure, tested for high gene editing efficiency | ☑Research | ☑GMP |
6. パンエンドヌクレアーゼ製品
| 品名 | グレード | 品番 | サイズ |
| Ubrinucelase™ Pan endonuclease | GMPグレード | UbNuC-G100 | 100KU |
| UbNuC-G500 | 500KU | ||
| UbNuC-G1000 | 1MU |
uBriGene社のウェブサイトは、こちら